 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Ceapro receives final court approval for merger with Aeterna Zentaris

TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ( Ceapro ) are pleased to...

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ( Ceapro ) are pleased to announce...

Aeterna Zentaris Inc. (TSE:AEZS) has released an update. Aeterna Zentaris Inc. has received final court approval to merge with Ceapro Inc. in a str...

Aeterna Zentaris Announces Merger Approval

Ceapro Inc (TSE:CZO) has released an update. Ceapro Inc. has received final court approval for its all-stock merger with Aeterna Zentaris, with com...

Ceapro Inc. Finalizes Merger with Aeterna Zentaris

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( Aeterna ) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ( Ceapro ) are pleased to...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( Aeterna ) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ( Ceapro ) are pleased to announce...

ISS states in its Aeterna Zentaris FOR recommendation that on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Volume (M)	896.00
52-Wk High	$3.38
52-Wk Low	$1.36

AEZS Aeterna Zentaris Inc.

About

Feed

News

Fundamentals